公开(公告)号：US10179162B2

公开(公告)日：2019-01-15

申请号：US14926438

申请日：2015-10-29

Applicant: Swedish Orphan Biovitrum AB (publ)

Inventor： Jonas Fransson ,  Ebba Florin-Robertsson

IPC: A61K38/20 ,  C07K14/545 ,  C07K14/715 ,  A61K38/17 ,  A61K9/00 ,  A61K47/26 ,  A61K9/10 ,  A61K47/02 ,  A61K47/18 ,  A61K38/00

Abstract: The present invention relates to pharmaceutical compositions comprising anakinra as an active compound in the absence of sodium citrate. The said pharmaceutical compositions are useful for the treatment of IL-1 mediated disorders and for decreasing nociceptive pain during such treatment.

公开(公告)号：US11324807B2

公开(公告)日：2022-05-10

申请号：US15569659

申请日：2016-04-27

Applicant: Swedish Orphan Biovitrum AB (publ)

Inventor： Ebba Florin-Robertsson ,  Jonas Fransson ,  Barry D. Moore

IPC: A61K38/20 ,  A61K9/00 ,  A61K47/18 ,  A61K47/20 ,  A61P27/02 ,  A61P27/14 ,  A61P27/04 ,  A61K47/02 ,  A61K47/12 ,  A61K47/22 ,  A61K47/26

Abstract: The present invention relates to compositions comprising anakinra, buffer, and optionally at least one osmolyte and optionally further excipients. Further, the present invention relates to use of said compositions for treatment of for example ophthalmic disorders.

公开(公告)号：US20180110836A1

公开(公告)日：2018-04-26

申请号：US15569659

申请日：2016-04-27

Applicant: Swedish Orphan Biovitrum AB (publ)

Inventor： Ebba Florin-Robertsson ,  Jonas Fransson ,  Barry D. Moore

IPC: A61K38/20 ,  A61K9/00 ,  A61K47/22 ,  A61K47/12 ,  A61K47/20 ,  A61K47/26 ,  A61K47/02 ,  A61K47/18 ,  A61P27/02 ,  A61P27/04 ,  A61P27/14

CPC classification number: A61K38/2006 ,  A61K9/0048 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61P27/02 ,  A61P27/04 ,  A61P27/14 ,  A61K2300/00

Abstract: The present invention relates to compositions comprising anakinra, buffer, and optionally at least one osmolyte and optionally further excipients. Further, the present invention relates to use of said compositions for treatment of for example ophthalmic disorders.